HISTORICAL P100 / #63

Abridge

Healthcare AI · United States

Historical ranking valuation$5.30BSource snapshot: Jun 19, 2026

Disclosed primary funding in this record

$757.5M

Sum of non-overlapping disclosed USD amounts in confirmed primary financing entries in this record, including separately labeled equity components; not verified lifetime funding. Excludes amounts already included in a later round, announced, reported, database-only, debt, secondary and unclassified events.

6 confirmed primary rounds with disclosed USD amounts · Record through 2026-09-25

THE BUSINESS

Get to know Abridge.

Abridge provides AI tools that turn clinical conversations into draft documentation for healthcare teams. Its platform has distinct clinician, nursing and revenue-cycle workflows, with health systems as its stated customers.

Abridge clinical platform overview ↗Source checked Sep 24, 2026

Valuation history

Valuations reported at the time of each round.

Apr 2026$5.3B reportedSeries E extension, reported · ReportedSource ↗

Funding history

Funding rounds, debt and other financing events.

8sourced events · record as of 2026-09-25

Abridge's issuer releases support five individually quantified post-2020 raises and a $15M aggregate across its earlier Seed and Series A, not the database's separate $15M Seed plus $10M Series A plus $5M Seed. An April 2026 $316M Series E extension and June 2026 Eli Lilly strategic equity investment are reported, but their amount/timing and the reported lifetime total cannot be reconciled from issuer releases; neither reported item contributes a source-confirmed USD subtotal. All dates here are announcement/report dates unless the source explicitly says closed; this is not a complete legal financing register or current cap table.

Jun 11, 2026LATEST SOURCED

primary

Eli Lilly strategic investment

Eli Lilly

Interview reporting identifies strategic equity investment but no amount, issued class, close date or separate valuation.

AmountUndisclosedValuationUndisclosed

Apr 202607

primary

Series E extension, reported

Investors undisclosed

Fortune reports an April close and $5.3B valuation; Sacra also describes $316M. The reported approximately $830M lifetime total conflicts with simple addition of issuer-announced prior amounts. Withhold a numeric additive amount pending primary reconciliation.

Amount$316M reportedValuation$5.3B reported

Jun 23, 202506

primary

Series E

Andreessen Horowitz (lead) · Khosla Ventures

Issuer says the round successfully closed; June 23 is the published announcement date, not an independently verified closing date.

Amount$300MValuationUndisclosed

Feb 17, 202505

primary

Series D

Elad Gil (lead) · IVP (lead) · Bessemer Venture Partners · California Health Care Foundation · CapitalG · CVS Health Ventures · K. Ventures · Lightspeed Venture Partners · +4 more

Amount$250MValuationUndisclosed

Feb 23, 202404

primary

Series C

Lightspeed Venture Partners (lead) · Redpoint Ventures (lead) · IVP · Spark Capital · Union Square Ventures · Bessemer Venture Partners · Wittington Ventures · Mass General Brigham Artificial Intelligence and Digital Innovation Fund · +2 more

Lightspeed is identified as lead and Redpoint as co-lead.

Amount$150MValuationUndisclosed

Oct 26, 202303

primary

Series B

Spark Capital (lead) · Bessemer Venture Partners · CVS Health Ventures · Kaiser Permanente Ventures · Lifepoint Health · Mayo Clinic · SCAN Group · UC Investments · +1 more

Amount$30MValuationUndisclosed

Aug 11, 202202

primary

Series A-1

Wittington Ventures (lead) · Union Square Ventures · Bessemer Venture Partners · Pillar Venture Capital · UPMC Enterprises · Yoshua Bengio · Whistler Capital

Amount$12.5MValuationUndisclosed

Oct 6, 202001

primary

Seed and Series A aggregate

Union Square Ventures (lead) · UPMC (lead) · Bessemer Venture Partners · Pillar · KdT Ventures · Esther Dyson · Aneesh Chopra · Zen Chu

Issuer reports $15M total across Seed and Series A as of launch without allocating dollars or exact closing dates to either round; the old separate $15M/$10M/$5M rows would double-count.

Amount$15M across two roundsValuationUndisclosed

Financing participants

Investors, lenders and other parties named in funding announcements.

Eli Lilly

Eli Lilly strategic investment · Jun 11, 2026 · Participant · primary · Reported · Reported source ↗

Andreessen Horowitz

Series E · Jun 23, 2025 · Lead participant · primary · Confirmed · Confirmed source ↗

Khosla Ventures

Series E · Jun 23, 2025 · Participant · primary · Confirmed · Confirmed source ↗

Elad Gil

Series D · Feb 17, 2025 · Lead participant · primary · Confirmed · Confirmed source ↗